Celldex director granted 26,000 stock options

Celldex Therapeutics director Herbert J. Conrad received an option grant for 26,000 shares of common stock.

Rhea-AI Filing Summary

Celldex Therapeutics director Herbert J. Conrad received an option grant for 26,000 shares of common stock. The non-qualified stock option has an exercise price of $34.09 per share and expires on June 25, 2036. This award, granted under the company’s 2021 Omnibus Equity Incentive Plan, brings his reported option holdings to 26,000 derivative shares.

Insider Trade Summary

Grant/Award: 26,000 shares

Grant/Award 1 txn

Insider CONRAD HERBERT J

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Non-Qualified Stock Option (right to buy)	26,000	$0.00	$0.00

Holdings After Transaction: Non-Qualified Stock Option (right to buy) — 26,000 contracts (Direct)

Footnotes (1)

1. F1. Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

Key Figures

Option grant size: 26,000 options Exercise price: $34.09 per share Expiration date: June 25, 2036 +1 more

4 metrics

Option grant size 26,000 options Non-qualified stock option grant to director on June 25, 2026

Exercise price $34.09 per share Conversion or exercise price for the granted options

Expiration date June 25, 2036 Option expiration for the 26,000-share grant

Total derivative holdings 26,000 derivative shares Total options held after the reported grant

Key Terms

Non-Qualified Stock Option (right to buy), 2021 Omnibus Equity Incentive Plan, Grant, award, or other acquisition

3 terms

Non-Qualified Stock Option (right to buy) financial

"security_title: "Non-Qualified Stock Option (right to buy)""

2021 Omnibus Equity Incentive Plan financial

"Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan."

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Celldex Therapeutics (CLDX) director Herbert J. Conrad receive in this Form 4?

Herbert J. Conrad received a grant of 26,000 non-qualified stock options. Each option allows him to buy one share of Celldex common stock at a fixed exercise price under the 2021 Omnibus Equity Incentive Plan.

What is the exercise price of Herbert J. Conrad’s new Celldex (CLDX) stock options?

The new options have an exercise price of $34.09 per share. This means Conrad can buy Celldex common stock at $34.09 regardless of future market price, subject to the plan’s vesting and exercise terms.

How many Celldex (CLDX) options does Herbert J. Conrad hold after this grant?

After the transaction, Herbert J. Conrad holds 26,000 derivative shares in the form of stock options. The Form 4 shows the total derivative position following the grant equals the 26,000 options awarded in this filing.

When do Herbert J. Conrad’s newly granted Celldex (CLDX) options expire?

The non-qualified stock options expire on June 25, 2036. After that date, any unexercised options will lapse, and Conrad will no longer be able to purchase Celldex shares under this specific award.

Under which equity plan were Herbert J. Conrad’s Celldex (CLDX) options granted?

The options were granted under Celldex’s 2021 Omnibus Equity Incentive Plan. This plan allows the company to issue stock-based awards like options to directors, executives, and employees as part of their compensation.

Does this Celldex (CLDX) Form 4 show a stock purchase or sale by Herbert J. Conrad?

The Form 4 reports a grant of non-qualified stock options, not an open-market purchase or sale. The transaction code “A” indicates a grant or award acquisition rather than buying or selling existing shares in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/29/2026 - 04:07 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CONRAD HERBERT J

(Last) (First) (Middle)

C/O CELLDEX THERAPEUTICS, INC.

53 FRONTAGE ROAD, SUITE 220

(Street)

HAMPTON NEW JERSEY 08827

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Celldex Therapeutics, Inc. [ CLDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)(1)	$34.09	06/25/2026(1)		A		26,000		06/25/2027	06/25/2036	Common Stock	26,000	$0	26,000	D

Explanation of Responses:

1. Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

	/s/ Sam Martin, attorney-in-fact for Herbert J. Conrad	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)